Who are Regadenoson central - peripheral's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Regadenoson MRI myocardial blood flow, SG, Regadenoson myocardial perfusion imaging, Regadenoson (Lexiscan), AD109, Regadenoson central -central.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/regadenoson-central-peripheral.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Regadenoson central - peripheral — Competitive Intelligence Brief

Regadenoson central - peripheral (Regadenoson central - peripheral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine receptor agonist. Area: Cardiovascular.

phase 3 Adenosine receptor agonist A2A receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Regadenoson central - peripheral (Regadenoson central - peripheral) — Lokien van Nunen. Regadenoson central - peripheral acts as an adenosine A2A receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Regadenoson central - peripheral TARGET	Regadenoson central - peripheral	Lokien van Nunen	phase 3	Adenosine receptor agonist	A2A receptor
Regadenoson MRI myocardial blood flow	Regadenoson MRI myocardial blood flow	University of Colorado, Denver	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
SG	SG	Arcus Biosciences, Inc.	marketed	Adenosine 2A receptor antagonist	A2A receptor (adenosine 2A receptor)
Regadenoson myocardial perfusion imaging	Regadenoson myocardial perfusion imaging	University of Colorado, Denver	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
Regadenoson (Lexiscan)	Regadenoson (Lexiscan)	Brigham and Women's Hospital	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
AD109	AD109	Apnimed	phase 3	Adenosine A2A receptor antagonist	Adenosine A2A receptor
Regadenoson central -central	Regadenoson central -central	Lokien van Nunen	phase 3	A2A receptor agonist	A2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine receptor agonist class)

Inotek Pharmaceuticals Corporation · 1 drug in this class
Lokien van Nunen · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Regadenoson central - peripheral — Competitive Intelligence Brief. https://druglandscape.com/ci/regadenoson-central-peripheral. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab